Srinagar, June 28: Six drug samples collected from Kashmir have failed quality standards in tests conducted by the Central Drugs Standard Control Organisation (CDSCO), raising concerns over pharmaceutical compliance and drug safety in the Union Territory.

Official sources said the samples were drawn from different pharmacies and supply points across the Kashmir region as part of routine surveillance and quality monitoring checks carried out by drug control authorities. The failed samples have been identified as “Not of Standard Quality” (NSQ) after laboratory analysis.
The medicines in question reportedly did not meet prescribed parameters related to composition, potency and quality standards laid down under the Drugs and Cosmetics Act. Authorities have initiated further scrutiny to trace the source of procurement, distribution chain and manufacturers responsible for the substandard products.
Following the findings, the Drug Control Department has been asked to conduct detailed inspections of stockists, wholesalers and retail pharmacies from where the samples were lifted. Officials said action will be taken against any violation of licensing norms, storage conditions or procurement from unauthorized suppliers.
Authorities have also begun efforts to issue alerts and ensure that any remaining stock of the identified batches is immediately withdrawn from circulation to prevent public use. The concerned manufacturers and suppliers are expected to be issued show-cause notices as part of the regulatory process.
Officials added that such quality surveillance drives are conducted regularly to ensure patient safety and maintain strict pharmaceutical standards across Jammu and Kashmir. They emphasized that strict enforcement measures will continue against any entity involved in the production or distribution of substandard medicines.
The development underscores ongoing concerns about drug quality monitoring and highlights the importance of strengthened regulatory oversight in the healthcare supply chain.